Akari Therapeutics (AKTX) Change in Account Payables (2014 - 2015)

Akari Therapeutics' (AKTX) quarterly Change in Account Payables came in at $682000.0 in Q2 2015, up 215.4% year-on-year from $216235.0 in Q2 2014, and up 196.46% quarter-over-quarter from -$707000.0 in Q1 2015.

Akari Therapeutics (AKTX) Change in Account Payables (2014 - 2015) Analysis & Trends

Akari Therapeutics has disclosed Change in Account Payables across 2 years of filings, most recently posting $682000.0 for Q2 2015.

  • Change in Account Payables for Q2 2015 came in at $682000.0, up 215.4% year-over-year; the trailing twelve-month figure through Jun 2015 was -$424000.0 (changed N/A YoY), and the FY2014 annual result was -$223000.0, up 67.01% from the prior year.
  • Change in Account Payables came in at $682000.0 for Q2 2015 at Akari Therapeutics, up from -$707000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $682000.0 in Q2 2015 to a low of -$707000.0 in Q1 2015.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Account Payables (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - -3.26 Mn
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - -
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - -
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn 35.60 Mn
9 Abivax 90.15 Bn 90.15 Bn - -9.42 Mn
10 Regeneron Pharmaceuticals 63.59 Bn 54.83 Bn 3.31 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2015 682,000.00
Jun 30, 2015 682,000.00
Mar 31, 2015 -707,000.00
Mar 31, 2015 -707,000.00
Jun 30, 2014 -591,000.00
Jun 30, 2014 -591,000.00
Mar 31, 2014 192,000.00
Mar 31, 2014 192,000.00